330 related articles for article (PubMed ID: 30022754)
21. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
Borowitz MJ; Devidas M; Hunger SP; Bowman WP; Carroll AJ; Carroll WL; Linda S; Martin PL; Pullen DJ; Viswanatha D; Willman CL; Winick N; Camitta BM;
Blood; 2008 Jun; 111(12):5477-85. PubMed ID: 18388178
[TBL] [Abstract][Full Text] [Related]
22. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001.
Vrooman LM; Blonquist TM; Harris MH; Stevenson KE; Place AE; Hunt SK; O'Brien JE; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
Blood Adv; 2018 Jun; 2(12):1449-1458. PubMed ID: 29941458
[TBL] [Abstract][Full Text] [Related]
23. Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study.
Yeoh AEJ; Lu Y; Chin WHN; Chiew EKH; Lim EH; Li Z; Kham SKY; Chan YH; Abdullah WA; Lin HP; Chan LL; Lam JCM; Tan PL; Quah TC; Tan AM; Ariffin H
J Clin Oncol; 2018 Sep; 36(26):2726-2735. PubMed ID: 30044693
[TBL] [Abstract][Full Text] [Related]
24. Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: The first nation-wide prospective multicenter study in China.
Cui L; Li ZG; Chai YH; Yu J; Gao J; Zhu XF; Jin RM; Shi XD; Zhang LP; Gao YJ; Zhang RD; Zheng HY; Hu SY; Cui YH; Zhu YP; Zou Y; Ng MHL; Xiao Y; Li JH; Zhang YH; He HL; Xian Y; Wang TY; Li CK; Wu MY;
Am J Hematol; 2018 Jul; 93(7):913-920. PubMed ID: 29675840
[TBL] [Abstract][Full Text] [Related]
25. Expression of Ik6 and Ik8 Isoforms and Their Association with Relapse and Death in Mexican Children with Acute Lymphoblastic Leukemia.
Reyes-León A; Juárez-Velázquez R; Medrano-Hernández A; Cuenca-Roldán T; Salas-Labadía C; Del Pilar Navarrete-Meneses M; Rivera-Luna R; López-Hernández G; Paredes-Aguilera R; Pérez-Vera P
PLoS One; 2015; 10(7):e0130756. PubMed ID: 26131904
[TBL] [Abstract][Full Text] [Related]
26. Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia.
Yao QM; Liu KY; Gale RP; Jiang B; Liu YR; Jiang Q; Jiang H; Zhang XH; Zhang MJ; Chen SS; Huang XJ; Xu LP; Ruan GR
BMC Cancer; 2016 Apr; 16():269. PubMed ID: 27067989
[TBL] [Abstract][Full Text] [Related]
27. Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study).
Nagafuji K; Miyamoto T; Eto T; Kamimura T; Taniguchi S; Okamura T; Ohtsuka E; Yoshida T; Higuchi M; Yoshimoto G; Fujisaki T; Abe Y; Takamatsu Y; Yokota S; Akashi K; Harada M
J Hematol Oncol; 2013 Feb; 6():14. PubMed ID: 23388549
[TBL] [Abstract][Full Text] [Related]
28. [Clinical Significance of Minimal Residual Disease in Pediatric Patients with
Xue YJ; Lu AD; Wang Y; Jia YP; Zuo YX; Zhang LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1303-1308. PubMed ID: 37846676
[TBL] [Abstract][Full Text] [Related]
29. Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis.
Ruggeri A; Michel G; Dalle JH; Caniglia M; Locatelli F; Campos A; de Heredia CD; Mohty M; Hurtado JM; Bierings M; Bittencourt H; Mauad M; Purtill D; Cunha R; Kabbara N; Gluckman E; Labopin M; Peters C; Rocha V
Leukemia; 2012 Dec; 26(12):2455-61. PubMed ID: 22555150
[TBL] [Abstract][Full Text] [Related]
30. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.
Biondi A; Valsecchi MG; Seriu T; D'Aniello E; Willemse MJ; Fasching K; Pannunzio A; Gadner H; Schrappe M; Kamps WA; Bartram CR; van Dongen JJ; Panzer-Grümayer ER
Leukemia; 2000 Nov; 14(11):1939-43. PubMed ID: 11069029
[TBL] [Abstract][Full Text] [Related]
31. Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia.
Yu CH; Jou ST; Su YH; Coustan-Smith E; Wu G; Cheng CN; Lu MY; Lin KH; Wu KH; Chen SH; Huang FL; Chang HH; Wang JL; Yen HJ; Li MJ; Chou SW; Ho WL; Liu YL; Chang CC; Lin ZS; Lin CY; Chen HY; Ni YL; Lin DT; Lin SW; Yang JJ; Ni YH; Pui CH; Yu SL; Yang YL
Cancer; 2023 Mar; 129(5):790-802. PubMed ID: 36537587
[TBL] [Abstract][Full Text] [Related]
32. Predictive Value of Dynamic Peri-Transplantation MRD Assessed By MFC Either Alone or in Combination with Other Variables for Outcomes of Patients with T-Cell Acute Lymphoblastic Leukemia.
Wang ZD; Wang YW; Xu LP; Zhang XH; Wang Y; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Wang YZ; Liu YR; Liu KY; Huang XJ; Chang YJ
Curr Med Sci; 2021 Jun; 41(3):443-453. PubMed ID: 34185250
[TBL] [Abstract][Full Text] [Related]
33. Combination of IKZF1 deletion and early molecular response show significant roles on prognostic stratification in Philadelphia chromosome-positive acute lymphoblastic leukemia patients.
Li H; Zhang W; Kuang P; Ye Y; Yang J; Dai Y; Lu X; Zheng Y; Liu T
Leuk Lymphoma; 2018 Aug; 59(8):1890-1898. PubMed ID: 29214878
[TBL] [Abstract][Full Text] [Related]
34. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
[TBL] [Abstract][Full Text] [Related]
35. Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood.
Mussolin L; Pillon M; Conter V; Piglione M; Lo Nigro L; Pierani P; Micalizzi C; Buffardi S; Basso G; Zanesco L; Rosolen A
J Clin Oncol; 2007 Nov; 25(33):5254-61. PubMed ID: 18024872
[TBL] [Abstract][Full Text] [Related]
36. Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia.
O'Connor D; Enshaei A; Bartram J; Hancock J; Harrison CJ; Hough R; Samarasinghe S; Schwab C; Vora A; Wade R; Moppett J; Moorman AV; Goulden N
J Clin Oncol; 2018 Jan; 36(1):34-43. PubMed ID: 29131699
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.
van Dongen JJ; Seriu T; Panzer-Grümayer ER; Biondi A; Pongers-Willemse MJ; Corral L; Stolz F; Schrappe M; Masera G; Kamps WA; Gadner H; van Wering ER; Ludwig WD; Basso G; de Bruijn MA; Cazzaniga G; Hettinger K; van der Does-van den Berg A; Hop WC; Riehm H; Bartram CR
Lancet; 1998 Nov; 352(9142):1731-8. PubMed ID: 9848348
[TBL] [Abstract][Full Text] [Related]
38. Combined IKZF1 and IG markers as new tools for diagnosis and minimal residual disease assessment in Tunisian B-ALL.
Besbes S; Hamadou WS; Boulland ML; Lefranc MP; Ben Youssef Y; Achour B; Khelif A; Fest T; Soua Z
Bull Cancer; 2016 Oct; 103(10):822-828. PubMed ID: 27614734
[TBL] [Abstract][Full Text] [Related]
39. Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL.
Kim M; Park J; Kim DW; Kim YJ; Jeon YW; Yoon JH; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim HJ; Min CK; Cho SG; Kim Y; Lee JW; Han K; Min WS; Lee S
Bone Marrow Transplant; 2015 Mar; 50(3):354-62. PubMed ID: 25501350
[TBL] [Abstract][Full Text] [Related]
40. Aberrant IKZF1 gene as relapse predictor in standard-risk pediatric patients with B-cell precursor acute lymphoblastic leukaemia.
Vshyukova VS; Krasko OV; Yanchanka DA; Meleshko AN
Int J Lab Hematol; 2022 Aug; 44(4):769-776. PubMed ID: 35505470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]